Skip to content
Boca Raton City Online – Lifestyle
Author:
Entrada Therapeutics, Inc.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
June 2, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 8, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 8, 2026
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
March 6, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences
March 4, 2026